19 
o Medical surveillance (e.g., serum samples for serologic 
changes; checks for possible physiologic changes related 
to product exposure) 
o Worker education 
,T Medical Surveillance of Biochemical Workers,” a Report on the 
CDC/NIOSH Ad Hoc Working Group on Medical Surveillance for 
Industry Applications of Biotechnology was published in the 
Recombinant DNA Bulletin, Vol. 5, No. 3, September, 1982. 
5. Environmental Protection Agency (EPA): EPA has established 
an in-house group to evaluate existing legal and regulatory 
mechanisms available to the agency regarding the applied genetics 
industry. Exploratory efforts have- also been initiated to 
evaluate beneficial uses of the products of this industry in 
reducing existing hazards to the environment. EPA has further 
conducted seminars dealing with containment levels and water 
decontamination. In 1982, EPA's Office of Exploratory Research 
issued a report entitled "Industrial Use of Applied Genetics and 
Organisms.” The report makes specific recommendations to the 
EPA: 
o Any environmental risks arising from industrial uses of 
applied genetics are speculative. At this time, there 
exists no compelling reason for the EPA to establish re- 
gulations in this area. 
o Should environmental hazards emerge in the future, it is 
probable that they can be handled within the existing 
[ 620 ] 
